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AGEING AND OSTEOARTHRITIS MARKERS IDENTIFIED BY MALDI
IMAGING MASS SPECTROMETRY
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Heeren z. yUniv. of Liverpool, Neston, United Kingdom; z FOM Inst.
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Purpose: Cartilage protein distribution and the changes that occur in
cartilage ageing and disease are essential in understanding the process
of cartilage ageing and age-related diseases such as osteoarthritis (OA).
Matrix assisted laser desorption ionization (MALDI) imaging mass
spectrometry (IMS) enables examination of proteins in-situ at a high
spatial resolution. This study utilised this methodology to investigate
the location and abundance of different cartilage proteins in ageing and
OA equine cartilage in order to determine changing molecular events
distinct between aging and disease.
Methods: For age-related studies samples were taken from skeletally
mature young and old horses. For OA studies skeletally mature donors
were chosen with mild macroscopic OA changes. 12 mm thick sections
were cut in duplicate. Following washing trypsin for digestion was
applied and Alpha-Cyano-4-hydroxycinnamic acid matrix deposited.
Synapt HDMS MALDI-Q-TOF was used to perform the IMS experiments.
Peptides were identiﬁed using MASCOT following MS/MS experiments.
Biomap software was used to generate ion images and quantify peptide
intensity. The data analysis workﬂow used Principal Component Anal-
ysis (PCA) and Discriminant Analysis (DA) for data interpretation.
Following IMS samples were stained with haematoxylin and eosin and
histologically assessed.
Results: Histological assessment revealed mild changes in the OA
samples alone. Protein proﬁling experiments directly from the tissue
sections identiﬁed extracellular matrix proteins including cartilage
oligomeric matrix protein, ﬁbromodulin, biglycan and type II
collagen. After combining all the spectra from the different condi-
tions and following DA, the resulting discriminant functions classiﬁed
the data in three groups according to their peptide proﬁle: young, old
and OA. Interestingly there was a large contribution of the old
samples to the negative part of DF1 indicating that peptides within
old samples were also present in OA samples. The spectra of young,
old and OA samples after MALDI-IMS experiments were analyzed
independently by PCA and DA to classify peptides speciﬁc to each
group (young versus old and old versus OA), thus producing a cata-
logue of peptides distinct in ageing and disease. Then protein
distribution differences were visualised and semi-quantiﬁed, through
the examination of peptide intensities in young, old and OA cartilage
Biomap. A number of OA and ageing markers were identiﬁed.
Signiﬁcant differences were evident for the peak intensity distribu-
tion of OA speciﬁc peptides including ﬁbronectin peptides m/z 1349.6
and m/z 1401.7 (p¼0.018, p¼0.02) and the hypothetical marker with
m/z 1366.5 (p¼0.001) between ageing and OA samples. Age-related
markers were also identiﬁed for COMP m/z 2256.1, the hypothetical
marker m/z 2415.9 and ﬁbromodulin peptide ELHLDHNQISR; m/z
1361.7 Furthermore there was a signiﬁcant reduction in the intensity
of this latter peptide (Figure 1) and biglycan peptide
NHLVEIPPNLPSSLVELR m/z 2027.2 (p¼0.001, p¼0.02) in OA (C)
compared to young (A) and old (B) cartilage indicating peptides
potentially targeted for degradation in OA.1063-4584/$ – see front matterConclusions: MALDI-IMS based molecular imaging provided a novel
platform to study cartilage ageing and disease enabling age and disease
speciﬁc markers in cartilage to be elucidated and spatially resolved as
well as identifying peptides targeted in early OA degradation.101
GLUCOCORTICOIDS INDUCE SENESCENCE IN PRIMARY HUMAN
TENOCYTES: IN VITRO AND IN VIVO EVIDENCE
R.C. Poulsen, A.C. Watts, R.J. Murphy, A.J. Carr, P.A. Hulley. Univ. of
Oxford, Oxford, United Kingdom
Synthetic glucocorticoids (GCs) are frequently used to treat painful and
inﬂamed tissues and joints. However GCs also cause unwanted side
effects, inhibiting cell proliferation as well as normal cell activity.
Whether these effects are transient or long-term is unknown. Inhibition
of cell proliferation can lead to either quiescence or senescence.
Whereas quiescence is reversible, senescence is irreversible in vivo and
hence leads to a permanent loss of normal cell functionality.
Purpose: The aim of this study was to determine whether GCs induce
senescence in human tenocytes in vitro and in vivo.
Methods: Characteristic features of cell senescence (b-galactsidase
activity at pH6 (SA-b-gal), active mTOR in cells in cycle arrest) were
examined in GC-treated primary human tenocytes. The effect of GCs on
activity of the two main pathways leading to cell senescence (p38/
p16INK4a and p53/p21cip) was determined by Western blotting. Gene
expression changes were assessed by RT-qPCR. Tendon biopsies were
taken from tendinopathy patients immediately prior to and seven-
weeks following GC injection. Markers of senescence were analysed in
biopsy specimens by immunohistochemistry.
Results: GC treatment of human tenocytes in vitro resulted in a higher
percentage of SA-b-gal positive cells. mTOR remained active despite cell
cycle arrest in GC-treated tenocytes. Increased p53 acetylation and
reduced levels of the p53 deacetylase sirtuin 1 were observed in GC-
treated tenocytes. Levels of p21cip, an anti-apoptosis/pro-senescence
modulator of p53 activity were also increased post-GC treatment.
Knockdown of p53 using RNAi or chemical inhibition of p53 activity
prevented GC-induced senescence. Preclusion of the GC-induced
reduction in sirtuin 1 levels either by adenoviral-mediated over-
expression of exogenous sirtuin 1 or by upregulation of endogenous
sirtuin 1 expression by glucose restriction (to emulate caloric restric-
tion) or treatment with resveratrol also prevented GC-induced
